CSF2 and melanoma: With a median follow up of 74 months, the median progression-free survival was 7.9 (95%CI, 4.4 to 32.4) months in patients who received lethally irradiated, autologous melanoma cells engineered by adenoviral mediated gene transfer to secrete GM-CSF (Figure 1A).